{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:27:23Z","timestamp":1786980443386,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:00:00Z","timestamp":1554336000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:00:00Z","timestamp":1554336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006221","name":"United States - Israel Binational Science Foundation","doi-asserted-by":"publisher","award":["2017369"],"award-info":[{"award-number":["2017369"]}],"id":[{"id":"10.13039\/100006221","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["U01MH101722"],"award-info":[{"award-number":["U01MH101722"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["U01MH101719"],"award-info":[{"award-number":["U01MH101719"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s00787-019-01326-4","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T10:24:47Z","timestamp":1554459887000},"page":"1035-1048","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Effectiveness and side effects of psychopharmacotherapy in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders: a systematic review"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-0376","authenticated-orcid":false,"given":"Mariela","family":"Mosheva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liran","family":"Korotkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel E.","family":"Gur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Weizman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doron","family":"Gothelf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,4]]},"reference":[{"key":"1326_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/pd.4613","volume":"35","author":"FR Grati","year":"2015","unstructured":"Grati FR, Molina Gomes D, Ferreira JCPB et al (2015) Prevalence of recurrent pathogenic microdeletions and microduplications in over 9500 pregnancies. Prenat Diagn 35:801\u2013809. \nhttps:\/\/doi.org\/10.1002\/pd.4613","journal-title":"Prenat Diagn"},{"key":"1326_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ddrr.2","volume":"14","author":"RJ Shprintzen","year":"2008","unstructured":"Shprintzen RJ (2008) Velo-cardio-facial syndrome: 30\u00a0years of study. Dev Disabil Res Rev 14:3\u201310. \nhttps:\/\/doi.org\/10.1002\/ddrr.2","journal-title":"Dev Disabil Res Rev"},{"key":"1326_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.71","author":"DM McDonald-McGinn","year":"2015","unstructured":"McDonald-McGinn DM, Sullivan KE, Marino B et al (2015) 22Q11.2 deletion syndrome. Nat Rev Dis Prim. \nhttps:\/\/doi.org\/10.1038\/nrdp.2015.71","journal-title":"Nat Rev Dis Prim"},{"key":"1326_CR4","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.schres.2006.04.007","volume":"87","author":"EWC Chow","year":"2006","unstructured":"Chow EWC, Watson M, Young DA, Bassett AS (2006) Neurocognitive profile in 22q11 deletion syndrome and schizophrenia. Schizophr Res 87:270\u2013278. \nhttps:\/\/doi.org\/10.1016\/j.schres.2006.04.007","journal-title":"Schizophr Res"},{"key":"1326_CR5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1176\/appi.ajp.2013.13070864","volume":"171","author":"M Schneider","year":"2014","unstructured":"Schneider M, Debban\u00e9 M, Bassett AS et al (2014) Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the international consortium on brain and behavior in 22q11.2 deletion syndrome. Am J Psychiatry 171:627\u2013639. \nhttps:\/\/doi.org\/10.1176\/appi.ajp.2013.13070864","journal-title":"Am J Psychiatry"},{"key":"1326_CR6","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1017\/S0033291713001669","volume":"44","author":"SX Tang","year":"2014","unstructured":"Tang SX, Yi JJ, Calkins ME et al (2014) Psychiatric disorders in 22q11.2 deletion syndrome are prevalent but undertreated. Psychol Med 44:1267\u20131277. \nhttps:\/\/doi.org\/10.1017\/S0033291713001669","journal-title":"Psychol Med"},{"key":"1326_CR7","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1097\/CHI.0b013e3181b76683","volume":"48","author":"T Green","year":"2009","unstructured":"Green T, Gothelf D, Glaser B et al (2009) Psychiatric disorders and intellectual functioning throughout development in velocardiofacial (22q11.2 deletion) syndrome. J Am Acad Child Adolesc Psychiatry 48:1060\u20131068. \nhttps:\/\/doi.org\/10.1097\/CHI.0b013e3181b76683","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1326_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/gim.2014.175","volume":"17","author":"WLA Fung","year":"2015","unstructured":"Fung WLA, Butcher NJ, Costain G et al (2015) Practical guidelines for managing adults with 22q11.2 deletion syndrome. Genet Med 17:599\u2013609. \nhttps:\/\/doi.org\/10.1038\/gim.2014.175","journal-title":"Genet Med"},{"key":"1326_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ejmg.2014.02.008","volume":"57","author":"A Vogels","year":"2014","unstructured":"Vogels A, Schevenels S, Cayenberghs R et al (2014) Presenting symptoms in adults with the 22q11 deletion syndrome. Eur J Med Genet 57:157\u2013162. \nhttps:\/\/doi.org\/10.1016\/j.ejmg.2014.02.008","journal-title":"Eur J Med Genet"},{"key":"1326_CR10","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jpeds.2011.02.039","volume":"159","author":"AS Bassett","year":"2011","unstructured":"Bassett AS, McDonald-McGinn DM, Devriendt K et al (2011) Practical guidelines for managing patients with 22q11.2 deletion syndrome. J Pediatr 159:332\u2013339. \nhttps:\/\/doi.org\/10.1016\/j.jpeds.2011.02.039","journal-title":"J Pediatr"},{"key":"1326_CR11","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. \nhttps:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"1326_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1089\/cap.2014.0075","volume":"27","author":"N Dori","year":"2017","unstructured":"Dori N, Green T, Weizman A, Gothelf D (2017) The effectiveness and safety of antipsychotic and antidepressant medications in individuals with 22q11.2 deletion syndrome. J Child Adolesc Psychopharmacol 27:83\u201390. \nhttps:\/\/doi.org\/10.1089\/cap.2014.0075","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1326_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1055\/s-0034-1398612","volume":"48","author":"WMA Verhoeven","year":"2015","unstructured":"Verhoeven WMA, Egger JIM (2015) Atypical antipsychotics and relapsing psychoses in 22q11.2 deletion syndrome: a long-term evaluation of 28 patients. Pharmacopsychiatry 48:104\u2013110. \nhttps:\/\/doi.org\/10.1055\/s-0034-1398612","journal-title":"Pharmacopsychiatry"},{"key":"1326_CR14","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1192\/bjp.bp.114.151837","volume":"206","author":"NJ Butcher","year":"2015","unstructured":"Butcher NJ, Fung WLA, Fitzpatrick L et al (2015) Response to clozapine in a clinically identifiable subtype of schizophrenia. Br J Psychiatry 206:484\u2013491. \nhttps:\/\/doi.org\/10.1192\/bjp.bp.114.151837","journal-title":"Br J Psychiatry"},{"key":"1326_CR15","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1212\/WNL.57.3.410","volume":"57","author":"WD Graf","year":"2001","unstructured":"Graf WD, Unis AS, Yates CM et al (2001) Catecholamines in patients with 22q11.2 deletion syndrome and the low-activity COMT polymorphism. Neurology 57:410\u2013416. \nhttps:\/\/doi.org\/10.1212\/WNL.57.3.410","journal-title":"Neurology"},{"key":"1326_CR16","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.4088\/JCP.v64n1004","volume":"64","author":"D Gothelf","year":"2003","unstructured":"Gothelf D, Gruber R, Presburger G et al (2003) Methylphenidate treatment for attention-deficit\/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open label study. J Clin Psychiatry 64:1163\u20131169","journal-title":"J Clin Psychiatry"},{"key":"1326_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1089\/cap.2011.0042","volume":"21","author":"T Green","year":"2011","unstructured":"Green T, Weinberger R, Diamond A et al (2011) The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. J Child Adolesc Psychopharmacol 21:589\u2013595. \nhttps:\/\/doi.org\/10.1089\/cap.2011.0042","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1326_CR18","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/nn1572","volume":"8","author":"D Gothelf","year":"2005","unstructured":"Gothelf D, Eliez S, Thompson T et al (2005) COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome. Nat Neurosci 8:1500\u20131502. \nhttps:\/\/doi.org\/10.1038\/nn1572","journal-title":"Nat Neurosci"},{"key":"1326_CR19","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s00702-012-0831-x","volume":"119","author":"T Green","year":"2012","unstructured":"Green T, Steingart L, Frisch A et al (2012) The feasibility and safety of S-adenosyl-l-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial. J Neural Transm 119:1417\u20131423. \nhttps:\/\/doi.org\/10.1007\/s00702-012-0831-x","journal-title":"J Neural Transm"},{"key":"1326_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0920-9964(98)00114-5","volume":"35","author":"D Gothelf","year":"1999","unstructured":"Gothelf D, Frisch A, Munitz H et al (1999) Clinical characteristics of schizophrenia associated with velo-cardio-facial syndrome. Schizophr Res 35:105\u2013112. \nhttps:\/\/doi.org\/10.1016\/S0920-9964(98)00114-5","journal-title":"Schizophr Res"},{"key":"1326_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaac.2014.10.002","volume":"54","author":"KG Jensen","year":"2015","unstructured":"Jensen KG, Juul K, Fink-Jensen A et al (2015) Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry 54:25\u201336. \nhttps:\/\/doi.org\/10.1016\/j.jaac.2014.10.002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1326_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1136\/jmg.2008.063800","volume":"46","author":"AS Bassett","year":"2009","unstructured":"Bassett AS, Chow EWC, Husted J et al (2009) Premature death in adults with 22q11.2 deletion syndrome. J Med Genet 46:324\u2013330. \nhttps:\/\/doi.org\/10.1136\/jmg.2008.063800","journal-title":"J Med Genet"},{"key":"1326_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/2045125311405566","volume":"1","author":"S Varma","year":"2011","unstructured":"Varma S, Bishara D, Besag FMC, Taylor D (2011) Clozapine-related EEG changes and seizures: dose and plasma-level relationships. Ther Adv Psychopharmacol 1:47\u201366. \nhttps:\/\/doi.org\/10.1177\/2045125311405566","journal-title":"Ther Adv Psychopharmacol"},{"key":"1326_CR24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1365-2788.2005.00708.x","volume":"49","author":"SCD Gladston","year":"2005","unstructured":"Gladston SCD (2005) Clozapine treatment of psychosis associated with velo-cardio-facial syndrome: benefits and risks. J Intellect Disabil Res 49:567\u2013570. \nhttps:\/\/doi.org\/10.1111\/j.1365-2788.2005.00708.x","journal-title":"J Intellect Disabil Res"},{"key":"1326_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1517\/eods.2.3.233.21376","volume":"2","author":"KC Lee","year":"2003","unstructured":"Lee KC, Finley PR, Alldredge BK (2003) Risk of seizures associated with psychotropic medications: emphasis on new drugs and new findings. Expert Opin Drug Saf 2:233\u2013247. \nhttps:\/\/doi.org\/10.1517\/eods.2.3.233.21376","journal-title":"Expert Opin Drug Saf"},{"key":"1326_CR26","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/ajmg.a.36928","volume":"167","author":"E Boot","year":"2015","unstructured":"Boot E, Butcher NJ, van Amelsvoort TAMJ et al (2015) Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. Am J Med Genet Part A 167:639\u2013645. \nhttps:\/\/doi.org\/10.1002\/ajmg.a.36928","journal-title":"Am J Med Genet Part A"},{"key":"1326_CR27","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1542\/peds.2008-0185","volume":"123","author":"AD Mosholder","year":"2009","unstructured":"Mosholder AD, Gelperin K, Hammad TA et al (2009) Hallucinations and other psychotic symptoms associated with the use of attention-deficit\/hyperactivity disorder drugs in children. Pediatrics 123:611\u2013616. \nhttps:\/\/doi.org\/10.1542\/peds.2008-0185","journal-title":"Pediatrics"},{"key":"1326_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.schres.2015.08.033","volume":"168","author":"Y-C Shyu","year":"2015","unstructured":"Shyu Y-C, Yuan S-S, Lee S-Y et al (2015) Attention-deficit\/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population-based study in Taiwan. Schizophr Res 168:161\u2013167. \nhttps:\/\/doi.org\/10.1016\/j.schres.2015.08.033","journal-title":"Schizophr Res"},{"key":"1326_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/schbul\/sbx113","volume":"44","author":"M Niarchou","year":"2017","unstructured":"Niarchou M, Calkins ME, Moore TM et al (2017) Attention deficit hyperactivity disorder symptoms and psychosis in 22q11.2 deletion syndrome. Schizophr Bull 44:1\u201310. \nhttps:\/\/doi.org\/10.1093\/schbul\/sbx113","journal-title":"Schizophr Bull"},{"key":"1326_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jad.2009.02.016","volume":"119","author":"EM Jolin","year":"2009","unstructured":"Jolin EM, Weller RA, Jessani NR et al (2009) Affective disorders and other psychiatric diagnoses in children and adolescents with 22q11.2 deletion syndrome. J Affect Disord 119:177\u2013180. \nhttps:\/\/doi.org\/10.1016\/j.jad.2009.02.016","journal-title":"J Affect Disord"},{"key":"1326_CR31","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1399-0004.2006.00569.x","volume":"69","author":"V Shashi","year":"2006","unstructured":"Shashi V, Keshavan MS, Howard TD et al (2006) Cognitive correlates of a functional COMT polymorphism in children with 22q11.2 deletion syndrome. Clin Genet 69:234\u2013238. \nhttps:\/\/doi.org\/10.1111\/j.1399-0004.2006.00569.x","journal-title":"Clin Genet"},{"key":"1326_CR32","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1136\/bmj.328.7444.879","volume":"328","author":"JN Jureidini","year":"2004","unstructured":"Jureidini JN, Doecke CJ, Mansfield PR et al (2004) Efficacy and safety of antidepressants for children and adolescents. BMJ 328:879\u2013883. \nhttps:\/\/doi.org\/10.1136\/bmj.328.7444.879","journal-title":"BMJ"},{"key":"1326_CR33","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1001\/archgenpsychiatry.2011.2048","volume":"69","author":"RD Gibbons","year":"2012","unstructured":"Gibbons RD, Brown CH, Hur K et al (2012) Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 69:580\u2013587. \nhttps:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.2048","journal-title":"Arch Gen Psychiatry"},{"key":"1326_CR34","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/schbul\/sbx005","volume":"43","author":"O Weisman","year":"2017","unstructured":"Weisman O, Guri Y, Gur RE et al (2017) Subthreshold psychosis in 22q11.2 deletion syndrome: multisite naturalistic study. Schizophr Bull 43:1079\u20131089. \nhttps:\/\/doi.org\/10.1093\/schbul\/sbx005","journal-title":"Schizophr Bull"},{"issue":"4","key":"1326_CR35","first-page":"305","volume":"20","author":"AC Stachon","year":"2011","unstructured":"Stachon AC, De Souza C (2011) Anxiety disorders and perceptual disturbances in adolescents with 22q11.2 deletion syndrome treated with SSRI: a case series. J Can Acad Child Adolesc Psychiatry. 20(4):305\u2013310","journal-title":"J Can Acad Child Adolesc Psychiatry."}],"container-title":["European Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-019-01326-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00787-019-01326-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-019-01326-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T16:02:33Z","timestamp":1595174553000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00787-019-01326-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,4]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["1326"],"URL":"https:\/\/doi.org\/10.1007\/s00787-019-01326-4","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,4]]},"assertion":[{"value":"12 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}